A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a lead-in Phase 1B Dose Escalation Portion) in Patients With Advanced or Metastatic Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Carotuximab (Primary) ; Axitinib
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRAXAR
- Sponsors TRACON Pharmaceuticals
- 04 Oct 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 04 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 07 Sep 2017 According to a TRACON Pharmaceuticals media release, company expects to report top-line progression-free survival (PFS) data from this study later this year.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History